Germany expects AstraZeneca to deliver 3M vaccine doses in February,Reuters says » 15:3001/2401/24/21
Germany expects AstraZeneca to deliver 3M doses of its COVID-19 vaccine in February despite the company's latest production problems, Health Minister Jens Spahn told Bild am Sonntag newspaper. AstraZeneca informed European Union officials it would cut deliveries of its COVID-19 vaccine to the bloc by 60% to 31M doses in the first quarter of the year due to production problems, a senior official told Reuters. Reference Link
J&J director says company could boost vaccine availability by spring, CNBC says » 16:1801/2201/22/21
Johnson & Johnson…
Johnson & Johnson board member Dr. Mark McClellan said that "if the clinical trial works out," the company may be able to significantly boost America's COVID-19 vaccine supply availability within a matter of weeks, CNBC's Emily DeCiccio reports. I do know that J&J is making a very large supply, going all out with its production, both here in the U.S. and elsewhere around the world, with the goal of having perhaps enough vaccines for 100 million Americans by spring, by this April or so," said the former FDA Commissioner in a Thursday evening interview on CNBC. Reference Link
AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says » 15:2501/2201/22/21
AstraZeneca has informed…
AstraZeneca has informed European Union officials that it would reduce deliveries of its coronavirus vaccine to the bloc by 60% to 31M doses in the first quarter of 2021 due to production issues, Reuters' Francesco Guarascio reports, citing a senior official. The company was forecast to deliver to the 27 EU countries roughly 80M shots by the end of March, the author notes, citing the official who was involved in the talks. Reference Link
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays » 15:0001/2201/22/21
Barclays analyst Emmanuel…
Barclays analyst Emmanuel Papadakis lowered the firm's price target on AstraZeneca to 9,000 GBp from 9,300 GBp and keeps an Overweight rating on the shares.
Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine » 12:0201/2201/22/21
Pfizer (PFE) and BioNTech…
Pfizer (PFE) and BioNTech (BNTX) announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021. COVAX is a global initiative coordinated by the Global Alliance for Vaccines and Immunization, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels. COVAX includes an Advanced Market Commitment financial mechanism that aims to ensure that 92 low- and lower-middle-income countries will be able to secure access to COVID-19 vaccines at the same time as higher-income countries. The first doses are expected to be delivered in the first quarter of 2021, subject to the negotiation and execution of supply agreements under the COVAX Facility structure. For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price. Financial terms of the agreement were not disclosed.
EU to see delay of AstraZeneca COVID vaccine delivery, FT reports » 11:5301/2201/22/21
The European Union will…
The European Union will experience a delay in the delivery of COVID-19 vaccines made by AstraZeneca in partnership with Oxford, the Financial Times reports. The company said that initial volumes of the vaccine will be "lower than originally anticipated," the report says. Reference Link
AstraZeneca informs EU Commission of vaccine delivery issues, Bild says » 10:3801/2201/22/21
A translation of a…
A translation of a German-language report from Bild indicates that AstraZeneca has informed the EU Commission that it will initially be able to deliver significantly less of the Oxford vaccine for COVID-19 after approval than had been anticipated. Reference Link
Coty promotes Stephane Delbos to chief procurement officer » 08:2001/2201/22/21
Coty (COTY) announced the…
Coty (COTY) announced the promotion of Stephane Delbos to chief procurement officer, or CPO, effective February 1. Delbos, who joined Coty in 2010 as global sourcing director, has been promoted from his current role as senior VP for transformation, indirect and procurement operations, where he has played an important role in driving forward Coty's broader transformation agenda. Delbos will join Coty's senior leadership team and report to Gordon von Bretten, chief transformation officer. Delbos is a senior procurement professional with over 18 years' experience in the beauty and pharmaceutical industries. Prior to joining Coty, he held several local and global procurement positions at Pfizer (PFE). In his new role, Delbos will be responsible for implementing Coty's multi-year procurement strategy, which includes achieving a significant cost reduction target by FY23, reducing complexity and strengthening Coty's new product pipeline. This forms an important element of Coty's transformation program, announced in 2020.
ViiV Healthcare announces FDA approval of Cabenuva » 16:4601/2101/21/21
GSK, PFE, JNJ
ViiV Healthcare, the…
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. FDA approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines, ViiV Healthcare's cabotegravir and Janssen's (JNJ) rilpivirine, dosed once monthly, as an option to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.
Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports » 15:2101/2101/21/21
Pfizer (PFE) has cut in…
Pfizer (PFE) has cut in half the volume of COVID-19 vaccines it will deliver to some EU countries this week, Reuters' Radu-Sorin Marinas, Jan Lopatka, and Tsvetelia Tsolova report, citing government officials. Pfizer and its partner BioNTech (BNTX) have declined to comment on the cuts beyond their statement last week, the report noted. Reference Link